Chang J. Zhao

No. 600 Tianhe Road
Guangzhou, 510630, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Comparative efficacy and safety of transarterial treatment strategies for hepatocellular carcinoma: a systematic review and network meta-analysis of randomized controlled trials.

Comparative efficacy and safety of transarterial treatment strategies for hepatocellular carcinoma: a systematic review and network meta-analysis of randomized controlled trials.

Journal: Frontiers in medicine

Published: May 14, 2026

Organic Cation-Regulated Citrate-Modified Monomeric Zirconium-Incorporated Polyoxotungstates: Structural Diversity and Catalytic Oxidation of Sulfides.

Organic Cation-Regulated Citrate-Modified Monomeric Zirconium-Incorporated Polyoxotungstates: Structural Diversity and Catalytic Oxidation of Sulfides.

Journal: Inorganic chemistry

Published: April 10, 2026

A dual-ion/immune checkpoint nanoplatform-activated pyroptosis/cGAS-STING signaling transform iMWA into systemic immunotherapy against HCC recurrence.

A dual-ion/immune checkpoint nanoplatform-activated pyroptosis/cGAS-STING signaling transform iMWA into systemic immunotherapy against HCC recurrence.

Journal: Materials today. Bio

Published: March 21, 2026

A rare solid tumor frequently misdiagnosed as lymphoma: primary colonic Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma.

A rare solid tumor frequently misdiagnosed as lymphoma: primary colonic Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma.

Journal: Virchows Archiv : an international journal of pathology

Published: March 13, 2026

Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.

Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 24, 2026

Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study.

Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study.

Journal: Gut

Published: December 22, 2025

A biomimetic magnetic MOF-based nanoplatform for H2S-mediated thermal re-sensitization and immune reprogramming in multimodal hyperthermia therapy.

A biomimetic magnetic MOF-based nanoplatform for H2S-mediated thermal re-sensitization and immune reprogramming in multimodal hyperthermia therapy.

Journal: Materials today. Bio

Published: October 24, 2025

Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: a multicenter study.

Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: a multicenter study.

Journal: International journal of surgery (London, England)

Published: September 16, 2025

The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations.

The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations.

Journal: Academic radiology

Published: September 12, 2025

Deep-learning-based artificial intelligence approaches for grading and progression prediction of clear cell renal cell carcinoma.

Deep-learning-based artificial intelligence approaches for grading and progression prediction of clear cell renal cell carcinoma.

Journal: iScience

Published: August 27, 2025

The effect of interval time of transcatheter arterial chemoembolization with drug-eluting beads on the efficacy and safety of unresectable hepatocellular carcinoma: a case-control study.

The effect of interval time of transcatheter arterial chemoembolization with drug-eluting beads on the efficacy and safety of unresectable hepatocellular carcinoma: a case-control study.

Journal: Frontiers in oncology

Published: August 16, 2025

Retraction notice to "Circular RNA hsa_circ_0005218 promotes the early recurrence of hepatocellular carcinoma by targeting the miR-31-5p/CDK1 pathway" [Heliyon 9 (2023) e14816].

Retraction notice to "Circular RNA hsa_circ_0005218 promotes the early recurrence of hepatocellular carcinoma by targeting the miR-31-5p/CDK1 pathway" [Heliyon 9 (2023) e14816].

Journal: Heliyon

Published: June 19, 2025

Showing 1-12 of 52

Last Updated: 09/26/2026